David A. Siegel Candel Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 36,485 shares of CADL stock, worth $200,302. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,485Holding current value
$200,302% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CADL
# of Institutions
82Shares Held
15.2MCall Options Held
570KPut Options Held
203K-
Acorn Capital Advisors, LLC New York, NY2.58MShares$14.2 Million8.54% of portfolio
-
Northpond Ventures, LLC1.94MShares$10.6 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.79MShares$9.81 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.62MShares$8.9 Million0.59% of portfolio
-
Geode Capital Management, LLC Boston, MA904KShares$4.96 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $159M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...